Huadong Medicine's Unit Gets Nod for Rilonacept for Injection's Registration

MT NewswiresDec 11 02:20 ET

Huadong Medicine (000963.SZ): The marketing authorization application for Linaclotide injection for the treatment of recurrent pericarditis has been approved.

Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou China-America Huadong Pharmaceutical Co., Ltd. (referred to as "...")

Zhitong FinanceDec 10 05:01 ET

Chinese Drug Administration Accepts Supplementary Application of Huadong Medicine's Unit for Psoriasis Drug

MT NewswiresDec 3 00:32 ET

Huadong Medicine's Drugs Included in National Insurance Catalog

MT NewswiresDec 1 22:01 ET

Huadong Medicine Co., Ltd's (SZSE:000963) Prospects Need A Boost To Lift Shares

Simply Wall StNov 29 21:36 ET

Huadong Medicine (000963.SZ): The products of its wholly-owned subsidiary are included in the national medical insurance catalog

On November 29, Gelonghui reported that huadong medicine (000963.SZ) announced that on November 28, 2024, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the "Notice on Printing and Distributing the National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug List (2024)" (Medicare Issuance [2024] No. 33) [hereinafter referred to as the "2024 National Medical Insurance Catalog"]. Some of the company's products were included in the "2024 National Medical Insurance Catalog". The company's wholly-owned subsidiary Hangzhou Zhongmei Huadong.

Gelonghui FinanceNov 29 04:42 ET